Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Lilly declares fourth-quarter 2024 dividend
11:31am, Monday, 28'th Oct 2024
INDIANAPOLIS , Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding commo
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel urg
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
04:20am, Monday, 28'th Oct 2024
One of these players has split its stock in the past. The other one hasn't.
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News
09:05pm, Sunday, 27'th Oct 2024
Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
Billionaire Stanley Druckenmiller Closed Out His Position in Eli Lilly Stock. 3 Reasons Why I'm Still a Buyer.
07:02am, Sunday, 27'th Oct 2024
Stanley Druckenmiller's Duquesne Family Office exited its position in Eli Lilly stock last quarter.
2 Soaring Growth Stocks That Are Still Worth Buying
09:30am, Saturday, 26'th Oct 2024
These two companies -- leaders in their industries -- look unstoppable.
NVS vs. LLY: Which Stock Is the Better Value Option?
12:41pm, Friday, 25'th Oct 2024
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value in
Lilly (LLY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:20am, Friday, 25'th Oct 2024
Beyond analysts' top -and-bottom-line estimates for Lilly (LLY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter en
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:05am, Friday, 25'th Oct 2024
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly Is Putting On Some Weight As Earnings Near
09:00am, Friday, 25'th Oct 2024
Eli Lilly and Company has shown rapid growth, driven by its weight loss drugs Mounjaro and Zepbound, with significant revenue increases. Despite impressive growth, I maintain a 'hold' rating due to th
In first dedicated study of a selective IL-13 inhibitor in patients previously treated with dupilumab, the majority of patients had a history of inadequate response to dupilumab EBGLYSS also provided
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
09:51am, Thursday, 24'th Oct 2024
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
09:27am, Thursday, 24'th Oct 2024
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals
